Glatiramer acetate-specific antibody titres in patients with relapsing ⁄ remitting multiple sclerosis and in experimental autoimmune encephalomyelitis

2018 ◽  
Vol 88 (1) ◽  
pp. e12673
Keyword(s):  
Multiple Sclerosis ◽  
Experimental Autoimmune Encephalomyelitis ◽  
Glatiramer Acetate ◽  
Specific Antibody ◽  
Autoimmune Encephalomyelitis ◽  
Relapsing Remitting ◽  
Antibody Titres ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Experimental Autoimmune

Mechanisms of Action of Intravenous Immunoglobulin (IVIG)

2000 ◽  
Vol 6 (2_suppl) ◽  
pp. S24-S26 ◽  
Author(s):  
Michel D Kazatchkine ◽  
Blanche Bellon ◽  
Srini V Kaveri
Keyword(s):  
Multiple Sclerosis ◽  
Autoimmune Disease ◽  
Experimental Autoimmune Encephalomyelitis ◽  
Intravenous Immunoglobulin ◽  
Mechanisms Of Action ◽  
Autoimmune Encephalomyelitis ◽  
Inflammatory Conditions ◽  
Relapsing Remitting ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Experimental Autoimmune

Therapeutic preparations of pooled normal polyspecific immunoglobulin G for intravenous use (intravenous immunoglobulin, IVIG) have been shown to be effective in the treatment of a number of autoimmune and systemic inflammatory conditions. IVIG prevents the occurrence of experimental autoimmune encephalomyelitis. Increasing evidence suggests that IVIG is of benefit in patients with relapsing-remitting multiple sclerosis. The present review discusses the immunoregulatory properties and mechanisms of action of IVIG in autoimmune disease.

scholarly journals When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?

2011 ◽  
Vol 2011 ◽  
pp. 1-11 ◽  
Author(s):  
Mona Alkhawajah ◽  
Joel Oger
Keyword(s):  
Multiple Sclerosis ◽  
Decision Making ◽  
Glatiramer Acetate ◽  
Major Question ◽  
Disease Modifying Drugs ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

For patients with Relapsing Remitting Multiple Scierosis Beta Interfaerons and Glatiramer Acetate were the first to be licensed for treatment. This review deals with one major question: when to initiate therapy? Through exploring the unique characteristics of the disease and treatement we suggest an approach that should be helpful in the process of decision-making.

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

2014 ◽  
Vol 20 (12) ◽  
pp. 1602-1608 ◽  
Author(s):  
Jordi Río ◽  
Alex Rovira ◽  
Mar Tintoré ◽  
Jaume Sastre-Garriga ◽  
Joaquín Castilló ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Scoring System ◽  
Clinical Activity ◽  
Disability Progression ◽  
Prospective Longitudinal Study ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Prospective Longitudinal

Background: In patients with relapsing–remitting multiple sclerosis (RRMS), a scoring system based on new magnetic resonance imaging (MRI) active lesions, relapses and sustained disability progression after a 1-year treatment with IFNβ predicted patient disability progression over time; however, this score had not been tested in patients receiving glatiramer acetate (GA). Objective: The objective of this study was to evaluate whether this previous scoring system can also be applied to patients treated with GA. Methods: This was a prospective, longitudinal study of 151 RRMS patients treated with GA. Their scores were constructed, based on the clinical and MRI activity after 1 year of therapy. Regression analysis was performed, in order to identify the response variables. Results: The total possible score range was 0–3. Patients with a score of ≥ 2 and those with clinical activity (with or without MRI activity) during their first year of treatment were at increased risk of continuing with relapses and/or sustained disability in the next 2 years (odds ratio (OR): 38.8; p < 0.0001 and OR: 7.8; p < 0.009, respectively). Conclusions: In RRMS patients treated with GA, a combination of clinical activity measures may have prognostic value for identifying patients with disease activity in the next 2 years of therapy.

Sign in / Sign up

Export Citation Format

Share Document